Free tool
FAERS Monitor: Eysuvis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210933 or its brand name (Eysuvis, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.
Reports
1,098
Serious
306
28% of reports
Hospitalization
89
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain232
- eye irritation153
- off label use100
- drug ineffective95
- ocular hyperaemia75
- product dose omission issue74
- headache64
- vision blurred60
- photophobia52
- fatigue51
- ocular discomfort50
- eye swelling46
- dry eye44
- pruritus39
- lacrimation increased36
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 12 |
| 2019 | 20 |
| 2020 | 31 |
| 2021 | 107 |
| 2022 | 141 |
| 2023 | 159 |
| 2024 | 185 |
| 2025 | 248 |
| 2026 | 150 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,061 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ocular discomfortSignal | 50 | 85.7 | 65.3 | 4,084 |
| eye painSignal | 232 | 79.1 | 70.5 | 17,784 |
| photophobiaSignal | 52 | 53.1 | 40.7 | 2,601 |
| eye irritationSignal | 153 | 51.1 | 44.1 | 7,459 |
| ocular hyperaemiaSignal | 75 | 30.3 | 24.4 | 2,099 |
| eye swellingSignal | 46 | 23.7 | 17.9 | 979 |
| lacrimation increasedSignal | 36 | 22.8 | 16.6 | 731 |
| dry eyeSignal | 44 | 16.9 | 12.6 | 643 |
| vision blurredSignal | 60 | 8.4 | 6.5 | 385 |
| product dose omission issueSignal | 74 | 4.8 | 3.9 | 223 |
| off label useSignal | 100 | 2.2 | 1.8 | 66 |
| headache | 64 | 2.0 | 1.5 | 30 |
| pruritus | 39 | 1.9 | 1.4 | 17 |
| drug ineffective | 95 | 1.4 | 1.1 | 10 |
| fatigue | 51 | 1.3 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.